Tardive Dyskinesia Treatment Market Report 2026

The tardive dyskinesia treatment market size has grown strongly in recent years. It will grow from $2.61 billion in 2025 to $2.84 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to prolonged use of antipsychotic medications, increasing awareness of tardive dyskinesia, limited availability of specialized treatment options, rising mental health disorder prevalence, growing hospital neurology departments.

The tardive dyskinesia treatment market size is expected to see strong growth in the next few years. It will grow to $3.9 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to development of novel dopamine-depleting therapies, expansion of deep brain stimulation adoption, increasing botulinum toxin applications, integration of telemedicine for movement disorder management, rising investment in patient-specific rehabilitation and cognitive therapies. Major trends in the forecast period include increasing adoption of dopamine-depleting agents and anticholinergic medications, rising preference for botulinum toxin injections for focal dyskinesia, growth in use of deep brain stimulation for refractory tardive dyskinesia, expansion of customized injection protocols and multi-target dbs approaches, integration of cognitive behavioral therapy and supportive rehabilitation programs.

The mounting prevalence of psychiatric disorders is poised to drive the tardive dyskinesia treatment market forward. Psychiatric disorders encompass diverse mental health issues impacting mood, cognition, conduct, and daily performance, typically needing professional evaluation and intervention. Their uptick arises from escalating stress and lifestyle strains like heavy workloads, social disconnection, and scant self-care time. Tardive dyskinesia treatment curbs uncontrolled motions, boosting therapy success and life quality for those on extended antipsychotics. For example, in November 2023, NHS England, a UK public health authority, found probable mental disorders in 20.3% of 8-16-year-olds, 23.3% of 17-19-year-olds, and 21.7% of 20-25-year-olds. Thus, the rising psychiatric disorders are fueling the tardive dyskinesia treatment market.

Leading companies in the tardive dyskinesia treatment market are advancing novel drugs like sprinkle capsule formulations to boost compliance for those with swallowing challenges. Sprinkle capsule formulations let users open capsules and mix contents into soft foods, simplifying intake for dysphagia sufferers. For instance, in July 2024, Neurocrine Biosciences Inc., a US biotech firm, rolled out Ingrezza sprinkle (valbenazine) capsules, the top vesicular monoamine transporter 2 (VMAT2) inhibitor for adults with tardive dyskinesia and Huntington's chorea. This daily oral option balances brain dopamine to tame involuntary movements, with a sprinkle design aiding hard-to-swallow cases.

In April 2025, Johnson & Johnson, a US pharma powerhouse, acquired Intra-Cellular Therapies for an undisclosed sum. This bolsters Johnson & Johnson's neuroscience dominance and foothold in booming mental health therapies. Intra-Cellular Therapies Inc. is a US pharma specialist in tardive dyskinesia solutions.

Major companies operating in the tardive dyskinesia treatment market are AbbVie Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Acadia Pharmaceuticals Inc., Upsher-Smith Laboratories LLC, Adamas Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the tardive dyskinesia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tardive dyskinesia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the tardive dyskinesia treatment market by increasing costs for imported medications, botulinum toxins, and medical devices used in deep brain stimulation. Hospital pharmacies, specialty clinics, and regions such as North America and Europe that rely on imports are most affected. While tariffs have raised treatment costs and slowed supply chains, they have also driven local manufacturing initiatives, promoted innovation in therapies, and encouraged diversification of treatment options.

The tardive dyskinesia treatment market research report is one of a series of new reports that provides tardive dyskinesia treatment market statistics, including tardive dyskinesia treatment industry global market size, regional shares, competitors with a tardive dyskinesia treatment market share, detailed tardive dyskinesia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the tardive dyskinesia treatment industry. This tardive dyskinesia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tardive dyskinesia treatment involves medical management and therapeutic interventions aimed at reducing or controlling the involuntary, repetitive movements that result from long-term use of dopamine receptor-blocking agents, particularly antipsychotics.

The main treatment types for tardive dyskinesia include medications, botulinum toxin injections, deep brain stimulation, and other therapies. Medications are drugs specifically used to manage and reduce the involuntary movements associated with prolonged antipsychotic use, with commonly prescribed options including valbenazine, amantadine, tetrabenazine, and clonazepam. These treatments are administered via oral, injectable, or transdermal routes. They are distributed through channels such as hospital and retail pharmacies and are used by end users including hospitals, specialty clinics, and other healthcare providers.

The tardive dyskinesia treatment market includes revenues earned by entities through botulinum toxin injection services, deep brain stimulation procedures, and diagnostic and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.